Staging Laparoscopy is Underutilized in the Management of Gastric Adenocarcinoma

  • Eric M. Groh
  • Shreya Gupta
  • Zachary J. Brown
  • Lindsey Enewold
  • Lauren A. Gamble
  • Jonathan M. Hernandez
  • Jeremy L. DavisEmail author
Gastrointestinal Oncology



Staging laparoscopy (SL) with peritoneal lavage is usually performed on a separate day from the planned resection and is recommended in patients with gastric adenocarcinoma as it can identify radiographically occult metastases and malignant cytology, thus altering prognosis and treatment. SL can be done on the same day as planned resection (SLSR) or with delayed resection (SLDR). The purpose of this study was to determine utilization of SL and factors associated with SLSR and SLDR, among patients diagnosed with gastric adenocarcinoma.


SEER-Medicare linked data were used to identify patients diagnosed with gastric adenocarcinoma from 2004 through 2013. SL were defined as a laparoscopy that occurred up to 3 months postdiagnosis. Multivariate logistic regression was used to identify factors associated with the utilization of SLSR and SLDR.


Of the 5610 patients with gastric adenocarcinoma who underwent a surgical procedure, 733 (13%) had a SL. Utilization of SL increased annually from 6.4% to 22.2% (p < 0.01). Receipt of SL was associated with patient demographics, tumor location, and treatment at a National Cancer Institute (NCI) Designated Cancer Center (CC). Of the 733 patients who underwent SL, 475 (65%) received further surgical procedures; 367 (77%) underwent SLSR, while 108 patients (23%) underwent SLDR. Compared with SLSR, SLDR was more common among patients who were younger, treated at an NCI-Designated CC and had proximal tumors.


SL for optimal preoperative staging remains underutilized in the management of gastric adenocarcinoma. Expanded use of laparoscopy as a distinct procedure could minimize unnecessary interventions.


Author Contributions

Study conception and design: EMG, ZJB, LE, JMH, JLD; Acquisition of data: EMG, ZJB, LE, SG; Analysis and interpretation of data: EMG, ZJB, LE, SG, JMH, JLD; Drafting of manuscript: EMG, ZJB, LE, SG, JMH, JLD; Critical revisions: EMG, ZJB, LE, SG, LG, JMH, JLD.


The authors declare they have no conflicts of interest.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Badgwell B, et al. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015;111(7):875–81.CrossRefGoogle Scholar
  3. 3.
    Ikoma N, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332–7.CrossRefGoogle Scholar
  4. 4.
    Mezhir JJ, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173–80.CrossRefGoogle Scholar
  5. 5.
    Bentrem D, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347–53.CrossRefGoogle Scholar
  6. 6.
    Sarela AI, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134–8.CrossRefGoogle Scholar
  7. 7.
    Karanicolas PJ, et al. Staging laparoscopy in the management of gastric cancer: a population-based analysis. J Am Coll Surg. 2011;213(5):644-51, e1.CrossRefGoogle Scholar
  8. 8.
    Snyder RA, et al. Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol. 2014;110(3):285–90.CrossRefGoogle Scholar
  9. 9.
  10. 10.
    National Cancer Institute. NCI-Designated Cancer Centers. Available at: Accessed 15 Nov 2017.
  11. 11.
    Klabunde CN, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.CrossRefGoogle Scholar
  12. 12.
    NCCN. NCCN clinical practice guidelines in oncology, gastric cancer. 2019.Google Scholar
  13. 13.
    Nassour I, et al. The yield of staging laparoscopy in gastric cancer is affected by racial and ethnic differences in disease presentation. Ann Surg Oncol. 2017;24(7):1787–94.CrossRefGoogle Scholar
  14. 14.
    Washington KJA. 7th Edition of the AJCC Cancer Staging Manual: stomach. 2010;17(12):3077–9.Google Scholar
  15. 15.
    Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):513–29.CrossRefGoogle Scholar
  16. 16.
    Reid-Lombardo KM, et al. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg. 2007;11(4):410–9; discussion 419–20.CrossRefGoogle Scholar
  17. 17.
    Burke EC, et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 1997;225(3):262–7.CrossRefGoogle Scholar
  18. 18.
    Son SY, et al. Rapid staining using the shorr method for intraoperative peritoneal washing cytology in advanced gastric cancer: a pilot study from a single institution. J Gastric Cancer. 2019;19(2):173–82.CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2019

Authors and Affiliations

  • Eric M. Groh
    • 1
  • Shreya Gupta
    • 1
  • Zachary J. Brown
    • 1
  • Lindsey Enewold
    • 2
  • Lauren A. Gamble
    • 1
  • Jonathan M. Hernandez
    • 1
  • Jeremy L. Davis
    • 1
    Email author
  1. 1.Surgical Oncology ProgramNational Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.Healthcare Assessment Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population SciencesNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations